On September 23, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Maryland School of Medicine (UMSOM) has joined its ongoing prostate cancer Cchek Study (Press release, Anixa Biosciences, SEP 23, 2019, View Source [SID1234539685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UMSOM is one of several sites across the United States participating in this study. Study enrollment will be led by Dr. Mohummad Siddiqui, who is also the Director of Urologic Oncology and Robotic Surgery and Chief of Urology at the Baltimore VA Medical Center.

"We are pleased to be working with Dr. Siddiqui and the University of Maryland School of Medicine to further develop our artificial intelligence based prostate cancer diagnostic test," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "Significant progress has been made in our efforts to advance the Cchek Prostate Cancer Confirmation test toward commercial launch later this year. We believe the Cchek early cancer detection platform will make a great impact on patient care, and we are pleased by the continued additions to our team of collaboration partners."